Hua-Ching Chang

Dr. Hua-Ching Chang

Taipei Medical University Hospital, Taipei, Taiwan
+1
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
KCKai-Wen Chuang
Kai-Wen Chuang
CHChe-Yuan Hsu
Che-Yuan Hsu
SHShiu-Wen Huang
Shiu-Wen Huang
HCHua-Ching Chang
Hua-Ching Chang

28 August 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
HCHua-Ching Chang
Hua-Ching Chang
TWTsung-Jen Wang
Tsung-Jen Wang
MLMing-Hsiu Lin
Ming-Hsiu Lin
TCTing-Jui Chen
Ting-Jui Chen
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are uncommon but life-threatening diseases mostly caused by drugs. Although various systemic immunomodulating agents have been used, their therapeutic efficacy has been inconsistent. This study aimed to provide an evidence-based review of systemic immunomodulating treatments for SJS/TEN. We reviewed 13 systematic review and meta-analysis articles published in the last 10 years. The use of systemic corticosteroids and IVIg is still controversial. An increasing number of studies have suggested the effectiveness of cyclosporine and biologic anti-TNF-α in recent years. There were also some promising results of combination treatments. Further large-scale randomized controlled trials are required to provide more definitive evidence of the effectiveness of these treatments. The pathogenesis of SJS/TEN has been elucidated in recent years and advances in the understanding of SJS/TEN may inspire the discovery of potential therapeutic targets.

1 December 2019 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
HCHua-Ching Chang
Hua-Ching Chang
MLMing-Hsiu Lin
Ming-Hsiu Lin
Yu-Chen HuangYu-Chen Huang
Yu-Chen Huang
THTsung-Yun Hou
Tsung-Yun Hou

12 November 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
CWChun-Chi Wang
Chun-Chi Wang
YTYu-Tang Tung
Yu-Tang Tung
HCHua-Ching Chang
Hua-Ching Chang
CLChang-Hsien Lin
Chang-Hsien Lin
Yang-ching ChenYang-ching Chen
Yang-ching Chen
High birth weight indicates the future risk of obesity and increased fat mass in childhood. Maternal gestational diabetes mellitus (GDM) or overweight are powerful predictors of high birth weight. Studies on probiotic supplementation during pregnancy have reported its benefits in modulating gut microbiota composition and improving glucose and lipid metabolism in pregnant women. Therefore, probiotic intervention during pregnancy was proposed to interrupt the transmission of obesity from mothers to newborns. Thus, we performed a meta-analysis to investigate the effect of probiotic intervention in pregnant women with GDM or overweight on newborn birth weight. We searched PubMed, EMBASE, Cochrane Library, and Web of Science databases up to 18 December 2019. Randomized controlled trials (RCTs) comparing pregnant women with GDM or overweight who received probiotic intervention during pregnancy with those receiving placebo were eligible for the analysis. Newborn birth weights were pooled to calculate the mean difference with a 95% confidence interval (CI). Two reviewers assessed the trial quality and extracted data independently. Seven RCTs involving 1093 participants were included in the analysis. Compared with the placebo, probiotics had little effect on newborn birth weight of pregnant women with GDM or overweight (mean difference = −10.27, 95% CI = −90.17 to 69.63, p = 0.801). The subgroup analysis revealed that probiotic intake by women with GDM decreased newborn birth weight, whereas probiotic intake by obese pregnant women increased newborn birth weight. Thus, no evidence indicates that probiotic intake by pregnant women with GDM or overweight can control newborn birth weight.


27 February 2019 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
PDF file
HCHua-Ching Chang
Hua-Ching Chang
CSChih-Wei Sung
Chih-Wei Sung
MLMing-Hsiu Lin
Ming-Hsiu Lin
Acne scars are common and challenging clinical complications of acne vulgaris. Ablative fractional carbon dioxide (CO2) laser is a well-established treatment for acne scars; however, some postlaser adverse effects have been noted. Autologous platelet-rich plasma (PRP) can improve tissue regeneration. Several studies have investigated the efficacy of combination therapy of CO2 laser and PRP for acne scars. To conduct a meta-analysis of the efficacy of PRP combined with ablative fractional CO2 laser for treating acne scars by examining clinical trial results. A systematic review was performed by searching PubMed, Embase, Cochrane Library, and Web of Science, and a meta-analysis was conducted to assess the clinical outcomes after combination therapy of PRP and ablative fractional CO2 laser compared with laser alone. We identified 4 eligible studies for the meta-analysis, including 3 randomized controlled trials. Our results demonstrated that clinical improvement after combination therapy was significantly higher than that after laser alone (odds ratio [OR] = 2.992, P = 0.001). Regarding major side effects, patients undergoing combination therapy experienced significantly shorter duration of crust compared with CO2 laser alone (standard mean difference = −1.140, P < 0.001); relatively shorter durations of erythema and edema were also noted after combination therapy. Furthermore, patient satisfaction rates were significantly higher after combination therapy than after laser alone (OR = 3.169, P = 0.002). The combination of autologous PRP and ablative fractional CO2 laser has synergistic positive effects on the clinical outcomes for acne scars and can accelerate the recovery of laser-damaged skin.